Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORA TESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORA TESTRYL.
DEPO-TESTOSTERONE vs ORA-TESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
50-400 mg IM every 2-4 weeks
Intramuscular injection: 50-100 mg every 2-4 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Category D/X
Category C
Androgen
Androgen